Reyon Pharmaceutical Co Ltd (102460) — Cash Flow Reinvestment Rate
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow Reinvestment Rate of 1.76x as of March 2025, reinvesting ₩4.25 Billion (capex ₩4.25 Billion plus investments ₩6.04 Million) from operating cash flow of ₩2.41 Billion. See Reyon Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Reyon Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2008–2023)
Historical reinvestment intensity for Reyon Pharmaceutical Co Ltd across 11 annual periods. For the full cash flow conversion analysis, see Reyon Pharmaceutical Co Ltd (102460) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Reyon Pharmaceutical Co Ltd (2008–2023)
Year-by-year capital reinvestment analysis for Reyon Pharmaceutical Co Ltd. See financial agility of Reyon Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 5.65x | ₩48.85 Billion | ₩8.65 Billion | ₩28.87 Billion | ▼ -57.4% |
| 2022 | 13.25x | ₩115.70 Billion | ₩8.73 Billion | ₩63.13 Billion | ▲ +30.1% |
| 2021 | 10.19x | ₩119.05 Billion | ₩11.68 Billion | ₩116.98 Billion | ▼ -37.1% |
| 2020 | 16.20x | ₩74.53 Billion | ₩4.60 Billion | ₩52.31 Billion | ▲ +120.5% |
| 2018 | 7.35x | ₩84.12 Billion | ₩11.45 Billion | ₩39.17 Billion | ▲ +144.8% |
| 2017 | 3.00x | ₩50.32 Billion | ₩16.76 Billion | ₩4.14 Billion | ▲ +186.4% |
| 2016 | 1.05x | ₩9.93 Billion | ₩9.47 Billion | ₩3.21 Billion | ▲ +334.7% |
| 2012 | 0.24x | ₩5.94 Billion | ₩24.65 Billion | ₩2.42 Billion | ▼ -37.8% |
| 2011 | 0.39x | ₩5.94 Billion | ₩15.34 Billion | ₩2.42 Billion | ▼ -1.2% |
| 2009 | 0.39x | ₩3.40 Billion | ₩8.68 Billion | ₩1.46 Billion | ▼ -41.6% |
| 2008 | 0.67x | ₩4.01 Billion | ₩5.99 Billion | ₩2.06 Billion | — |